Arteriovenous fistula is a cardiovascular disorder characterized by an abnormal connection between a vein and an artery. In a person having arteriovenous fistula, the blood flow pathway from arteries to the vein is altered and it bypasses the capillaries due to which the tissues below the bypassed capillaries get diminished blood supply. The disease generally occurs in legs. Arteriovenous fistula can be symptomatized by purplish and bulging veins, swelling in the arms and the legs, fatigue and decreased blood pressure. Some of the complications associated with arteriovenous fistula include deep vein thrombosis, leg pain, heart failure and bleeding. Vascular Therapies, Inc. is in the process of developing sirolimus as a mTOR protein inhibitor for the treatment of arteriovenous fistula. Proteon Therapeutics, Inc. is in the process of developing PRT-201 as an extracellular matrix protein modulator for the treatment of arteriovenous fistula. Some of the companies having the pipeline of arteriovenous fistula include Proteon Therapeutics, Inc., Vascular Therapies, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.